Pinsent Masons hires leading planning expert Emrys Parry

26 Jan 2017 | 03:56 pm | 1 min. read

International law firm Pinsent Masons has further expanded its planning and consenting team with the appointment of Emrys Parry as a Strategic Planning Adviser working across its Infrastructure, Energy and Real Estate sectors.

Emrys Parry joins from the Planning Inspectorate and is a legal associate of the Royal Town Planning Institute (RTPI), as well as a past chairman of the Compulsory Purchase Association. Prior to joining the inspectorate, he was a member of the Infrastructure Planning Commission (IPC) and he also led the Planning and Regeneration Division of Bond Pearce LLP solicitors where he specialised in property development and town and country planning.

With extensive experience of the Development Consent Order (DCO) regime and compulsory purchase law, Emrys has been a member of the Panels examining the Rookery South Energy from Waste Power Station, the Preesall Underground Gas Storage applications, the Thames Tideway Tunnel and the A14 upgrade programme.

Also starting at the firm is Emma Harling-Phillips, following the announcement of her appointment in October. She joins the London planning and consenting team from DLA Piper in London and will be focussing on the Infrastructure, Energy and Real Estate sectors. 

Iain Gilbey, Head of Planning, Environment, Energy and Infrastructure consenting at Pinsent Masons, comments: "Emrys is one of the UK’s most respected DCO, planning and compulsory purchase lawyers and his appointment, along with Emma's, are excellent additions to our market leading team. I'm certain that their in-depth knowledge of the planning and compulsory purchase system will be of immense value to our clients. Our practice continues to go from strength-to strength as we advise a growing number of key clients across our sectors."

Pinsent Masons is ranked the number one planning law firm by Planning Magazine. The team has advised on more DCO projects than any other law firm, including the largest road and power station schemes. The team operates nationally in the UK and internationally.

Latest press releases

Show me all press releases

Pinsent Masons advises NTR plc on 54MW portfolio of co-located solar and battery storage projects in Ireland

Multinational law firm Pinsent Masons has advised NTR PLC on the acquisition of a 54MW portfolio of co-located solar and battery storage projects in County Wexford, Ireland, from renewable energy developer RES.

Pinsent Masons advises on Four Seasons Care Homes portfolio migration

Multinational law firm Pinsent Masons has advised propco investor LDC Care Homes and its asset and investment manager Elevation Advisors on the migration of a care homes portfolio from Four Seasons Health Care Group (FSHC) to new operators.

Pinsent Masons advises Teva Pharmaceuticals on €84m sale of its consumer healthcare brand portfolio to Karo Pharma AB.

Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises NTR plc on 54MW portfolio of co-located solar and battery storage projects in Ireland

Multinational law firm Pinsent Masons has advised NTR PLC on the acquisition of a 54MW portfolio of co-located solar and battery storage projects in County Wexford, Ireland, from renewable energy developer RES.

Pinsent Masons advises on Four Seasons Care Homes portfolio migration

Multinational law firm Pinsent Masons has advised propco investor LDC Care Homes and its asset and investment manager Elevation Advisors on the migration of a care homes portfolio from Four Seasons Health Care Group (FSHC) to new operators.

Pinsent Masons advises Teva Pharmaceuticals on €84m sale of its consumer healthcare brand portfolio to Karo Pharma AB.

Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts